Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer

TL;DR

This review explores new immunotherapy strategies for treating biliary tract cancer, a difficult-to-treat cancer with poor outcomes.

Contribution

The paper provides a comprehensive overview and analysis of adoptive cell therapy strategies and their challenges in biliary tract cancer.

Findings

Adoptive cell immunotherapy shows promise as a new treatment avenue for biliary tract cancer.

Key challenges include heterogeneity and immunosuppression in BTC, which need to be addressed for effective therapy.

Optimization strategies for ACT are discussed to improve clinical translation and outcomes.

Abstract

Biliary tract cancer (BTC) is a highly heterogeneous malignancy originating from the biliary epithelium or gallbladder mucosa, characterized by strong invasiveness and poor prognosis. Although surgery remains the primary curative strategy, most patients are diagnosed at advanced stages, limiting surgical opportunities. The traditional gemcitabine plus cisplatin chemotherapy regimen, although a standard treatment, has limited efficacy and often leads to drug resistance. In recent years, adoptive cell immunotherapy has emerged as a promising new avenue for BTC treatment.

This review systematically elaborates on the research progress of various ACT strategies in BTC, including chimeric antigen receptor T cells, tumor-infiltrating lymphocytes, natural killer cells, cytokine-induced killer cells, and T-cell receptor-engineered T cells. Furthermore, it comprehensively analyzes current key challenges and discusses future directions and optimization strategies regarding these therapies.

This review summarizes recent progress in adoptive cell therapy for biliary tract cancer and discusses optimization strategies to facilitate clinical translation.

Figures